TACE治疗中晚期原发性肝癌108例生存分析  

Survival Analysis of 108 Cases with Advanced Primary Liver Cancer Treated by Transcatheter Arterial Chemoembolization

作　　者：沈玲[1] 朱海超 黄建锋[1] 楚建军[1] 

机构地区：[1]苏州大学附属第四人民医院肿瘤科,江苏无锡214000 [2]宁波市传染病医院感染科

出　　处：《肿瘤防治研究》2011年第10期1163-1166,共4页Cancer Research on Prevention and Treatment

摘　　要：目的探讨经导管肝动脉化疗栓塞术(TACE)治疗中晚期原发性肝癌(primary liver cancer,PLC)的生存率及其影响因素。方法回顾性分析108例接受TACE治疗的中晚期PLC患者临床资料;寿命表法计算生存率,Log-rank法单因素分析预后因素,Cox比例风险模型确定独立危险因素。结果 TACE治疗后6、12、24、36、48月生存率分别为59.26%、34.41%、14.03%、10.23%、5.12%;单因素分析显示,肿瘤最大直径、门静脉癌栓及远处转移是影响生存率的重要因素,Cox比例风险回归模型分析显示肿瘤最大直径>10 cm、存在门静脉癌栓是影响生存率的独立危险因素。结论 TACE是治疗中晚期PLC的有效方法;肿瘤大小和门静脉癌栓是影响患者预后的重要因素。Objective To evaluate the survival rate and prognostic factors of transcatheter arterial chemo- embolization（TACE） for advanced primary liver cancer （PLC）. Methods Clinical and follow-up data of 1118 patients with advanced PLC treated by TACE were retrospectively analyzed. Survival rate was calcu- lated by life table method. Log-rank univariable analysis and Cox regression analysis were performed to determine the predictors of survival. Results The cumulative survival rate at 6, 12, 24, 36 and 48 months were 59. 26% ,34. 415, 14.3%,10.23% and 5.12%, respectively. Univariate analysis revealed that the maximum diameter of tumor, metastasis and portal vein tumor thrombus were major factors affecting the survival. Cox＇s proportional hazard regression model demonstrated that the maximum diameter of tumor≥lO cm and existence of portal vein tumor thrombus were the independent risk factors affecting the survival. Conclusion TACE is an effective treatment for advanced PLC. Tumor size and portal vein tumor thrombus significantly affect the survival of advanced PLC patients.

关 键 词：原发性肝癌 经导管肝动脉化疗栓塞术 生存分析 COX比例风险回归模型 

分 类 号：R735.7[医药卫生—肿瘤]